Does the media refer more to MIRM or KALV?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 9 mentions for KalVista Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.20 beat KalVista Pharmaceuticals' score of 1.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KALV or APGE more profitable?

Apogee Therapeutics' return on equity of -32.64% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Apogee Therapeutics N/A -32.64% -31.25%

Does the media refer more to KALV or APGE?

In the previous week, Apogee Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 11 mentions for Apogee Therapeutics and 9 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.00 beat Apogee Therapeutics' score of 0.88 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or KALV more profitable?

Scholar Rock's return on equity of -163.52% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% KalVista Pharmaceuticals N/A -341.44% -111.94%

Does the media refer more to SRRK or KALV?

In the previous week, KalVista Pharmaceuticals had 2 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for KalVista Pharmaceuticals and 7 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.34 beat KalVista Pharmaceuticals' score of 1.00 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COGT or KALV more profitable?

Cogent Biosciences' return on equity of -104.27% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% KalVista Pharmaceuticals N/A -341.44% -111.94%

Does the media refer more to COGT or KALV?

In the previous week, Cogent Biosciences and Cogent Biosciences both had 9 articles in the media. KalVista Pharmaceuticals' average media sentiment score of 1.00 beat Cogent Biosciences' score of 0.69 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

KalVista Pharmaceuticals (KALV) Competitors

$27.00 0.00 (0.00%)

As of 06/12/2026

Compare

KALV vs. MIRM, APGE, SRRK, COGT, and GRFS

Should you buy KalVista Pharmaceuticals stock or one of its competitors? MarketBeat compares KalVista Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KalVista Pharmaceuticals include Mirum Pharmaceuticals (MIRM), Apogee Therapeutics (APGE), Scholar Rock (SRRK), Cogent Biosciences (COGT), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does KalVista Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Mirum Pharmaceuticals currently has a consensus target price of $138.36, indicating a potential upside of 39.26%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.33%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Mirum Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.62	-$23.36M	-$13.61	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 9 mentions for KalVista Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.20 beat KalVista Pharmaceuticals' score of 1.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

KalVista Pharmaceuticals has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Summary

Mirum Pharmaceuticals beats KalVista Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Apogee Therapeutics?

KalVista Pharmaceuticals (NASDAQ:KALV) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

79.0% of Apogee Therapeutics shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

KalVista Pharmaceuticals currently has a consensus price target of $30.60, indicating a potential upside of 13.33%. Apogee Therapeutics has a consensus price target of $114.56, indicating a potential upside of 29.70%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Apogee Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Apogee Therapeutics' return on equity of -32.64% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Apogee Therapeutics	N/A	-32.64%	-31.25%

KalVista Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 11 mentions for Apogee Therapeutics and 9 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.00 beat Apogee Therapeutics' score of 0.88 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Summary

Apogee Therapeutics beats KalVista Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Scholar Rock's return on equity of -163.52% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

KalVista Pharmaceuticals has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

In the previous week, KalVista Pharmaceuticals had 2 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for KalVista Pharmaceuticals and 7 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.34 beat KalVista Pharmaceuticals' score of 1.00 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 26.75%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.33%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Summary

Scholar Rock beats KalVista Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

KalVista Pharmaceuticals has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Cogent Biosciences' return on equity of -104.27% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Cogent Biosciences presently has a consensus target price of $43.73, indicating a potential upside of 32.11%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.33%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Cogent Biosciences and Cogent Biosciences both had 9 articles in the media. KalVista Pharmaceuticals' average media sentiment score of 1.00 beat Cogent Biosciences' score of 0.69 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cogent Biosciences beats KalVista Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Grifols?

Grifols (NASDAQ:GRFS) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Grifols has a net margin of 5.54% compared to KalVista Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Grifols has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Grifols has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	40.21
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

In the previous week, KalVista Pharmaceuticals had 8 more articles in the media than Grifols. MarketBeat recorded 9 mentions for KalVista Pharmaceuticals and 1 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat KalVista Pharmaceuticals' score of 1.00 indicating that Grifols is being referred to more favorably in the media.

Company	Overall Sentiment
Grifols	Very Positive
KalVista Pharmaceuticals	Positive

Grifols currently has a consensus price target of $10.00, indicating a potential upside of 30.89%. KalVista Pharmaceuticals has a consensus price target of $30.60, indicating a potential upside of 13.33%. Given Grifols' higher probable upside, equities analysts clearly believe Grifols is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Grifols beats KalVista Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get KalVista Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALV vs. The Competition

Export

Metric	KalVista Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.44B	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-7.80	18.84	24.00	24.42
Price / Sales	1,008.07	324.96	514.36	111.24
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	9.96	3.98	10.54	6.82
Net Income	-$109.52M	$75.79M	$3.57B	$337.56M
7 Day Performance	0.04%	1.57%	0.60%	1.17%
1 Month Performance	1.01%	-0.73%	1.56%	3.16%
1 Year Performance	108.33%	23.44%	25.42%	30.58%

KalVista Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALV KalVista Pharmaceuticals	3.114 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100	News Coverage Positive News Analyst Upgrade Short Interest Decrease
MIRM Mirum Pharmaceuticals	4.128 of 5 stars	$93.58 +0.1%	$137.64 +47.1%	+100.2%	$5.70B	$521.31M	N/A	140	Gap Up
APGE Apogee Therapeutics	3.2757 of 5 stars	$83.01 -4.5%	$114.56 +38.0%	+98.6%	$5.38B	N/A	N/A	91	Insider Trade
SRRK Scholar Rock	3.5369 of 5 stars	$43.80 -1.1%	$56.00 +27.9%	+36.1%	$5.31B	N/A	N/A	140	Positive News
COGT Cogent Biosciences	2.4836 of 5 stars	$31.16 +0.5%	$43.73 +40.3%	+367.5%	$5.30B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALV) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KalVista Pharmaceuticals (KALV) Competitors

KALV vs. MIRM, APGE, SRRK, COGT, and GRFS

How does KalVista Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does KalVista Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does KalVista Pharmaceuticals compare to Scholar Rock?

Summary

How does KalVista Pharmaceuticals compare to Cogent Biosciences?

Summary

How does KalVista Pharmaceuticals compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV vs. The Competition

KalVista Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KalVista Pharmaceuticals (KALV) Competitors

KALV vs. MIRM, APGE, SRRK, COGT, and GRFS

How does KalVista Pharmaceuticals compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or KALV?

Which has preferable valuation & earnings, MIRM or KALV?

Does the media refer more to MIRM or KALV?

Which has more risk & volatility, MIRM or KALV?

Is MIRM or KALV more profitable?

Summary

How does KalVista Pharmaceuticals compare to Apogee Therapeutics?

Do institutionals and insiders have more ownership in KALV or APGE?

Do analysts prefer KALV or APGE?

Is KALV or APGE more profitable?

Which has better earnings & valuation, KALV or APGE?

Does the media refer more to KALV or APGE?

Which has more volatility & risk, KALV or APGE?

Summary

How does KalVista Pharmaceuticals compare to Scholar Rock?

Do institutionals & insiders have more ownership in SRRK or KALV?

Is SRRK or KALV more profitable?

Which has higher valuation and earnings, SRRK or KALV?

Does the media refer more to SRRK or KALV?

Do analysts recommend SRRK or KALV?

Which has more volatility & risk, SRRK or KALV?

Summary

How does KalVista Pharmaceuticals compare to Cogent Biosciences?

Which has higher earnings and valuation, COGT or KALV?

Which has more volatility and risk, COGT or KALV?

Is COGT or KALV more profitable?

Do analysts rate COGT or KALV?

Does the media refer more to COGT or KALV?

Summary

How does KalVista Pharmaceuticals compare to Grifols?

Is GRFS or KALV more profitable?

Which has more risk and volatility, GRFS or KALV?

Which has preferable valuation and earnings, GRFS or KALV?

Does the media prefer GRFS or KALV?

Do analysts rate GRFS or KALV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV vs. The Competition

KalVista Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools